# Effect of PF-00734200 in Subjects With Type 2 Diabetes

> **NCT00618007** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 289 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** PF-00734200 30 mg QD
- **DRUG:** PF-00734200 20 mg QD
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00618007
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 289 (ACTUAL)
- **Last updated:** 2011-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00618007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00618007, "Effect of PF-00734200 in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00618007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*